Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting and Unaudited Financial Results under Regulation 30 and 33 of SEBI LODR
Date of Board Meeting / Approval: Tuesday, 10th November, 2026 (03:00 PM to 03:40 PM IST)
Audit Opinion: Unmodified conclusion (clean)
Auditor's Comment: Nothing has come to our attention that causes us to believe that the Statement contains any material misstatement.
Key Financial Highlights [₹ in lakhs]
Standalone Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹9,453.19 (vs ₹7,626.33 in Q2 FY26 - +24.0% YoY)
- Total Income: ₹9,650.17
- Profit Before Tax: ₹1,918.19 (vs ₹1,256.95 in Q2 FY26)
- Net Profit: ₹1,529.98 (vs ₹936.37 in Q2 FY26 - +63.4% YoY)
- EPS: ₹2.93 (vs ₹1.80 in Q2 FY26)
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹17,861.81 (vs ₹14,654.23 in H1 FY26 - +21.9% YoY)
- Total Income: ₹18,215.20
- Profit Before Tax: ₹3,539.43 (vs ₹2,569.03 in H1 FY26)
- Net Profit: ₹2,788.18 (vs ₹1,921.24 in H1 FY26 - +45.1% YoY)
- EPS: ₹5.35 (vs ₹3.69 in H1 FY26)
Other Equity: ₹26,734.12 (as of September 30, 2026 vs ₹23,938.04 as of March 31, 2026)
Cash and Cash Equivalents: ₹447.64 (as of September 30, 2026 vs ₹230.45 as of March 31, 2026)
Debt:
- Short-term Borrowings: ₹191.48
- Long-term Borrowings: ₹448.46
- Total Borrowings: ₹639.94
Consolidated Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹9,907.11 (vs ₹7,872.90 in Q2 FY26 - +25.8% YoY)
- Total Income: ₹10,057.54
- Profit Before Tax: ₹1,887.23 (vs ₹1,204.69 in Q2 FY26)
- Net Profit: ₹1,495.02 (vs ₹882.77 in Q2 FY26 - +69.4% YoY)
- EPS: ₹2.88 (vs ₹1.73 in Q2 FY26)
- Profit attributed to Owners: ₹1,500.94
- Profit attributed to Non-controlling interests: ₹(5.92)
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹18,671.65 (vs ₹15,131.53 in H1 FY26 - +23.4% YoY)
- Total Income: ₹18,930.85
- Profit Before Tax: ₹3,539.81 (vs ₹2,451.56 in H1 FY26)
- Net Profit: ₹2,779.56 (vs ₹1,800.28 in H1 FY26 - +54.4% YoY)
- EPS: ₹5.38 (vs ₹3.53 in H1 FY26)
- Profit attributed to Owners: ₹2,801.74
- Profit attributed to Non-controlling interests: ₹(22.18)
Other Equity: ₹26,581.57 (attributable to owners of parent as of September 30, 2026)
Cash and Cash Equivalents: ₹566.88 (as of September 30, 2026)
Segment-wise Performance:
The company is primarily engaged in the business of diagnostic centers for carrying out various pathology and radiology services. There are no separate reportable segments as per Ind AS 108 - Operating Segments.
Corporate Actions:
Not Specified
Other Significant Information:
Subsidiaries included in consolidation:
1. Suraksha Speciality LLP
2. Suraksha Radiology Private Limited
3. Suraksha Advanced Radiology Private Limited
4. Asian Institute of Immunology and Rheumatology LLP (AIIR)
5. Fetomat Wellness Private Limited
6. Suraksha Salvia LLP
Subsidiary Performance (before consolidation adjustments):
- Total assets: ₹3,731.60 lakhs as at September 30, 2026
- Total revenues: ₹526.39 lakhs for Q2 FY26 and ₹955.09 lakhs for H1 FY26
- Total net loss after tax: ₹41.85 lakhs for Q2 FY26 and ₹159.69 lakhs for H1 FY26
Exceptional Items: None
Change in Accounting Policy: Not specified
Forward-looking Guidance: Not provided